Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France

Inflammatory Bowel Diseases

Volumn 16, Issue 6, 2010, Pages 916-924

  Chevaux, Jean Baptiste ^a   Nani, Abdelbasset ^a   Oussalah, Abderrahim ^a   Venard, Véronique ^a   Bensenane, Mouni ^a   Belle, Arthur ^a   Gueant, Jean Louis ^a   Bigard, Marc André ^a   Bronowicki, Jean Pierre ^a   Peyrin Biroulet, Laurent ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

HBV; HCV; Inflammatory bowel disease

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; HEPATITIS B ANTIBODY; HEPATITIS B ANTIGEN; HEPATITIS C ANTIBODY; INFLIXIMAB;

ADULT; ARTICLE; COLON CROHN DISEASE; ENTERITIS; FEMALE; FRANCE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS; VACCINATION;

ADOLESCENT; ADULT; FEMALE; FRANCE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; PREVALENCE; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL HEPATITIS VACCINES; YOUNG ADULT;

EID: 77952679364     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21147     Document Type: Article

References (37)

1. Longo F, Hebuterne X, Tran A, et al. Prevalence of hepatitis C in patients with chronic inflammatory bowel disease in the region of Nice and evaluation of risk factors. Gastroenterol Clin Biol. 2000;24:77-81. (Pubitemid 30117236)
2. Biancone L, Pavia M, Del Vecchio Blanco G, et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis. 2001;7: 287-294. (Pubitemid 33062093)
3. Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol. 2009;104:57-63.
4. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis. 2007;13:1453-1454. (Pubitemid 350206866)
5. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365. (Pubitemid 39120128)
6. Wendling D, Di Martino V, Prati C, et al. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine. 2009;76:308-311.
7. Papa A, Mocci G, Bonizzi M, et al. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586.
8. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. Clin Exp Rheumatol. 2007;25:888-889.
9. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis. 2009;doi:10.1016.
10. Fong TL, Valinluck B, Govindarajan S, et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology. 1994;107:196-199. (Pubitemid 24195362)
11. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35:1944-1949.
12. Peyrin-Biroulet L, Gueant-Rodriguez RM, Chen M, et al. Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn's disease. Am J Gastroenterol. 2008;103:399-406. (Pubitemid 351248710)
13. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753. (Pubitemid 43764536)
14. Prévalence des hépatites B et C en France en 2004. Institut de Veille Sanitaire; 2004.
15. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2008; 29:29.
16. Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008;49:652-657.
17. Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, et al. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther. 2008;28:984-993.
18. Dubois F, Desenclos JC, Mariotte N, et al. Hepatitis C in a French population-based survey, 1994: seroprevalence, frequency of viremia, genotype distribution, and risk factors. The Collaborative Study Group. Hepatology. 1997;25:1490-1496.
19. O236 du 2 avril 1996 relative aux modalités de désinfection des endoscopes dans les lieux de soins. Bull Epidemiol Hebd. 1996;22:97-99.
20. Denis F, Abitbol V, Aufrere A. Evolution of strategy and coverage rates for hepatitis B vaccination in France, a country with low endemicity. Med Mal Infect. 2004;34:149-158. (Pubitemid 38529815)
21. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol. 2003;30:1624-1625. (Pubitemid 36835467)
22. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974-976.
23. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834-1840. (Pubitemid 44166594)
24. Wagner D, Wagenbreth I, Stachan-Kunstyr R, et al. Failure of vaccination against hepatitis B with Gen H-B-Vax-D in immunosuppressed heart transplant recipients. Clin Investig. 1992;70:585-587.
25. Worns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008;103:138-146.
26. Pallone F, Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut. 1998;43:735-736. (Pubitemid 28539644)
27. Jafarzadeh A, Shokri F. The antibody response to HBs antigen is regulated by coordinated Th1 and Th2 cytokine production in healthy neonates. Clin Exp Immunol. 2003;131:451-456. (Pubitemid 36324136)
28. Clark FL, Drummond MW, Chambers S, et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma. Ann Oncol. 1998;9:385-387. (Pubitemid 28273030)
29. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519-528. (Pubitemid 351665421)
30. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45: 507-539.
31. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factoralpha- blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36:1188-1194.
32. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol. 2008;43:397-401. (Pubitemid 351958904)
33. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis. 2007;13: 508-509. (Pubitemid 46668261)
34. Yang F, Robotham JM, Nelson HB, et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol. 2008;82:5269-5278. (Pubitemid 351705235)
35. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42:315-322.
36. Villa F, Rumi MG, Signorelli C, et al. Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. Eur J Gastroenterol Hepatol. 2005;17:1243-1245. (Pubitemid 41527444)
37. Tilg H, Vogelsang H, Ludwiczek O, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut. 2003;52:1728-1733. (Pubitemid 37510393)